R. A. Sperling, P. S. Aisen, and L. A. Beckett, Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, vol.7, pp.280-92, 2011.

M. S. Albert, S. T. Dekosky, and D. Dickson, The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, vol.7, pp.270-279, 2011.

G. M. Mckhann, D. S. Knopman, and H. Chertkow, The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup, Alzheimers Dement, vol.7, issue.3, pp.263-272, 2011.

E. R. Peskind, R. Riekse, and J. F. Quinn, Safety and acceptability of the research lumbar puncture, Alzheimer Dis Assoc Disord, vol.19, issue.4, pp.220-225, 2005.

P. Lewczuk, P. Riederer, O. Bryant, and S. E. , Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry, World J Biol Psychiatry, vol.2017, pp.1-85

A. M. Fagan and R. J. Perrin, Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease, Biomark Med, vol.6, issue.4, pp.455-76, 2012.

P. Lewczuk and J. Kornhuber, Neurochemical dementia diagnostics in Alzheimer's disease: where are we now and where are we going?, Expert Rev Proteomics, vol.8, issue.4, pp.447-58, 2011.

H. Hampel, K. Burger, and S. J. Teipel, Core candidate neurochemical and imaging biomarkers of Alzheimer's disease, Alzheimers Dement, vol.4, pp.38-48, 2008.

O. Hansson, H. Zetterberg, and P. Buchhave, Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, Lancet Neurol, vol.5, pp.228-262, 2006.

N. Mattsson, H. Zetterberg, and O. Hansson, CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment, JAMA, vol.302, pp.385-93, 2009.

R. C. Petersen, Mild cognitive impairment as a diagnostic entity, J Intern Med, vol.256, issue.3, pp.183-94, 2004.

M. Shoji, E. Matsubara, M. Kanai, M. Watanabe, T. Nakamura et al., Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease, J Neurol Sci, vol.158, issue.2, pp.134-174, 1998.

P. Lewczuk, H. Esselmann, and M. Otto, Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau, Neurobiol Aging, vol.25, issue.3, pp.273-81, 2004.

A. Roche, S. Gény, and C. , Decreased sA?PP?, A?38, and A?40 cerebrospinal fluid levels in frontotemporal dementia, J Alzheimers Dis, vol.26, issue.3, pp.553-63, 2011.

J. Wiltfang, H. Esselmann, M. Bibl, M. Hüll, H. Hampel et al., Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low-and high-CSF A beta 40 load, J Neurochem, vol.101, issue.4, pp.1053-1062, 2007.

S. Slaets, L. Bastard, N. Martin, J. J. Sleegers, K. Van-broeckhoven et al., Cerebrospinal fluid A?1-40 improves differential dementia diagnosis in patients with intermediate P-tau 181P levels, J Alzheimers Dis, vol.36, issue.4, pp.759-67, 2013.

M. Nutu, H. Zetterberg, E. Londos, L. Minthon, K. Nägga et al., Evaluation of the cerebrospinal fluid amyloid-?1-42/amyloid-?1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders, Dement Geriatr Cogn Disord, vol.36, issue.1-2, pp.99-110, 2013.

I. Baldeiras, I. Santana, and M. J. Leitão, Cerebrospinal fluid A?40 is similarly reduced in patients with frontotemporal lobar degeneration and Alzheimer's disease, J Neurol Sci, vol.358, issue.1-2, pp.308-324, 2015.

J. Dumurgier, S. Schraen, and A. Gabelle, Cerebrospinal fluid amyloid-? 42/ 40 ratio in clinical setting of memory centers: a multicentric study, Alzheimers Res Ther, vol.7, issue.1, p.30, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01842465

M. Sauvée, G. Didierlaurent, C. Latarche, M. C. Escanyé, J. L. Olivier et al., Additional use of A? 42 /A? 40 ratio with cerebrospinal fluid biomarkers P-tau and A? 42 increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice, J Alzheimers Dis, vol.41, issue.2, pp.377-86, 2014.

P. Lewczuk, N. Lelental, P. Spitzer, J. M. Maler, and J. Kornhuber, Amyloid-? 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays, J Alzheimers Dis, vol.43, issue.1, pp.183-91, 2015.

P. E. Spies, D. Slats, J. M. Sjögren, B. P. Kremer, F. R. Verhey et al., The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia, Curr Alzheimer Res, vol.7, issue.5, pp.470-476, 2010.

H. Struyfs, B. Van-broeck, M. Timmers, E. Fransen, K. Sleegers et al., Diagnostic accuracy of cerebrospinal fluid amyloid-? isoforms for early and differential dementia diagnosis, J Alzheimers Dis, vol.45, issue.3, pp.813-835, 2015.

S. Janelidze, H. Zetterberg, N. Mattsson, S. Palmqvist, H. Vanderstichele et al., CSF A?42/A?40 and A?42/A?38 ratios: better diagnostic markers of Alzheimer disease, Ann Clin Transl Neurol, vol.3, issue.3, pp.154-65, 2016.

O. Bousiges, B. Cretin, T. Lavaux, N. Philippi, B. Jung et al., Diagnostic value of cerebrospinal fluid biomarkers (Phospho-Tau181, total-Tau, A?42, and A?40) in prodromal stage of Alzheimer's disease and dementia with Lewy bodies, J Alzheimers Dis, vol.51, issue.4, pp.1069-83, 2016.

S. Lehmann, C. Delaby, and G. Boursier, Relevance of A?42/40 ratio for detection of Alzheimer disease pathology in clinical routine: the PLMR scale, Front Aging Neurosci, vol.10, p.138, 2018.

I. Baldeiras, I. Santana, and M. J. Leitão, Addition of the A?42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment, Alz Res Ther, vol.10, p.33, 2018.

A. Dorey, A. Perret-liaudet, Y. Tholance, A. Fourier, and I. Quadrio, Cerebrospinal fluid A?40 improves the interpretation of A?42 concentration for diagnosing Alzheimer's disease, Front Neurol, vol.6, p.247, 2015.

P. Lewczuk, R. Zimmermann, J. Wiltfang, and J. Kornhuber, Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers. Neural Transm (Vienna), vol.116, pp.1163-1170, 2009.

P. Lewczuk, J. Kornhuber, G. Dementia-competence, . Network, J. B. Toledo et al., Validation of the Erlangen score algorithm for the prediction of the development of dementia due to Alzheimer's disease in pre-dementia subjects, J Alzheimers Dis, vol.48, issue.2, p.887, 2015.

O. Hansson, H. Zetterberg, P. Buchhave, U. Andreasson, E. Londos et al., Prediction of Alzheimer's disease using the CSF Abeta42/ Abeta40 ratio in patients with mild cognitive impairment, Dement Geriatr Cogn Disord, vol.23, issue.5, pp.316-336, 2007.

J. Hertze, L. Minthon, H. Zetterberg, E. Vanmechelen, K. Blennow et al., Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years, J Alzheimers Dis, vol.21, issue.4, pp.1119-1147, 2010.

L. Parnetti, D. Chiasserini, P. Eusebi, D. Giannandrea, G. Bellomo et al., Performance of A?1-40, A?1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment, J Alzheimers Dis, vol.29, issue.1, pp.229-267, 2012.

L. Frölich, O. Peters, and P. Lewczuk, Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia, Alzheimers Res Ther, vol.9, issue.1, p.84, 2017.

T. T. Seppala, O. Nerg, and A. M. Koivisto, CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings, Neurology, vol.78, pp.1568-75, 2012.

D. A. Wolk, I. D. Grachev, and C. Buckley, Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology, Arch Neurol, vol.68, pp.1398-403, 2011.

P. Lewczuk and J. Kornhuber, Do we still need positron emission tomography for early Alzheimer's disease diagnosis?, Brain, vol.139, issue.11, p.60, 2016.

K. Blennow, H. Hampel, M. Weiner, and H. Zetterberg, Cerebrospinal fluid and plasma biomarkers in Alzheimer disease, Nat Rev Neurol, vol.6, pp.131-175, 2010.

K. Buerger, M. Ewers, and T. Pirttila, CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease, Brain, vol.129, pp.3035-3076, 2006.

K. Blennow, A. Wallin, and O. Hager, Low frequency of post-lumbar puncture headache in demented patients, Acta Neurol Scand, vol.88, pp.221-224, 1993.

P. Lewczuk, A. Matzen, K. Blennow, L. Parnetti, J. L. Molinuevo et al., Cerebrospinal fluid A?42/40 corresponds better than A?42 to amyloid PET in Alzheimer's disease, J Alzheimers Dis, vol.55, issue.2, pp.813-835, 2017.

N. Mattsson, P. S. Insel, M. Donohue, S. Landau, W. J. Jagust et al., Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer's disease, Brain, vol.138, issue.3, pp.772-83, 2015.

S. Palmqvist, N. Mattsson, and O. Hansson, Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography, Brain, vol.126, pp.1226-1262, 2016.

S. Janelidze, J. Pannee, and A. Mikulskis, Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment, JAMA Neurol, vol.74, issue.12, pp.1492-501, 2017.

A. Leuzy, K. Chiotis, and S. G. Hasselbalch, Pittsburgh compound B imaging and cerebrospinal fluid amyloid-? in a multicentre European memory clinic study, Brain, vol.139, issue.9, pp.2540-53, 2016.

S. E. Schindler, J. D. Gray, and B. A. Gordon, Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging, Alzheimers Dement, 2018.

D. R. Thal, J. Attems, and M. Ewers, Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies, J Alzheimers Dis, vol.42, issue.4, pp.421-430, 2014.

P. Selnes, K. Blennow, and H. Zetterberg, Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid, Cerebrospinal Fluid Res, vol.7, p.10, 2010.

D. Van-westen, D. Lindqvist, and K. Blennow, Cerebral white matter lesionsassociations with A? isoforms and amyloid PET, Sci Rep, vol.6, p.20709, 2016.

N. A. Verwey, W. M. Van-der-flier, K. Blennow, C. Clark, S. Sokolow et al., A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease, Ann Clin Biochem, vol.46, pp.235-275, 2009.

A. Perret-liaudet, M. Pelpel, Y. Tholance, B. Dumont, H. Vanderstichele et al., Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes, J Alzheimers Dis, vol.31, pp.13-20, 2012.

M. J. Leitão, I. Baldeiras, S. Herukka, M. Pikkarainen, V. Leinonen et al., Chasing the effects of pre-analytical confounders -a multicenter study on CSF-AD biomarkers, Front Neurol, vol.6, p.153, 2015.

L. Bastard, N. , D. Deyn, P. P. Engelborghs, and S. , Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid, Clin Chem, vol.61, pp.734-777, 2015.

A. Fourier, E. Portelius, H. Zetterberg, K. Blennow, I. Quadrio et al., Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability, Clin Chim Acta, vol.449, pp.9-15, 2015.

M. Bjerke, E. Portelius, L. Minthon, A. Wallin, H. Anckars¨ater et al., Confounding factors influencing amyloid beta concentration in cerebrospinal fluid, Int J Alzheimers Dis, 2010.

D. Campo, M. Mollenhauer, B. Bertolotto, A. Engelborghs, S. Hampel et al., Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update, Biomark Med, vol.6, pp.419-449, 2012.

N. Mattsson, U. Andreasson, S. Persson, M. C. Carrillo, S. Collins et al., CSF biomarker variability in the Alzheimer's Association QC program work group, Alzheimers Dement, vol.9, pp.251-61, 2013.

P. Lewczuk, G. Beck, H. Esselmann, R. Bruckmoser, R. Zimmermann et al., Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides, Clin Chem, vol.52, issue.2, pp.332-336, 2006.

C. Gervaise-henry, G. Watfa, E. Albuisson, A. Kolodziej, B. Dousset et al., Cerebrospinal fluid A? 42 /A? 40 as a means to limiting tube-and storagedependent pre-analytical variability in clinical setting, J Alzheimers Dis, vol.57, issue.2, pp.437-482, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02450425

E. Willemse, K. Van-uffelen, B. Brix, S. Engelborghs, H. Vanderstichele et al., How to handle adsorption of cerebrospinal fluid amyloid ? (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the A?42/A?40 ratio, Alzheimers Dement, vol.13, issue.8, pp.885-92, 2017.

H. M. Vanderstichele, S. Janelidze, and L. Demeyer, Optimized standard operating procedures for the analysis of cerebrospinal fluid A?42 and the ratios of A? isoforms using low protein binding tubes, J Alzheimers Dis, vol.53, issue.3, pp.1121-1153, 2016.